Expanding the Drug Development Toolkit with Proteomics

On this episode of Translating Proteomics, co-hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss how clinical researchers can leverage proteomics for drug development. Some of the themes covered in this episode include: · Proteomics and pre-clinical models · How proteomics can drive patient selection · Choosing the right end points in clinical trials Chapters 00:00 – 01:06 – Introduction 01:06 – 06:51 – Proteomics in pre-clinical studies 06:51 – 11:40 – The importance of choosing the right model for preclinical work 11:40 – 17:10 – How proteomics is used in Phase I/II clinical trials 17:10 – 19:29 – Proteomics tools in patient selection 19:29 – 24:33 – Useful information that we get from proteomics that we can’t get from genomics or transcriptomics 24:33 – 28:14 – Proteomics in Phase III clinical trials and picking the best indications of drug efficacy 28:14 – 29:19 - Understanding why clinical trials fail 29:19 – End - Outro Resources The National Cancer Institute’s webpage covering how clinical trials work Preprint on the miBrain model - An example of a new in vitro brain model Geary et al., 2021 - Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical Trials Wasko et al., 2024 - Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer The NCI-MATCH trail: Lessons for precision oncology – Report on a large-scale trial using genomic biomarkers to match cancer patients to treatments Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer – Study using proteomics to understand mechanisms of resistance to a cancer drug